View Older Stories View More Recent Stories

Nov 1, 2017 09:05AM Actinium Pharmaceuticals Announces Multiple Posters/Abstracts Accepted for 59th Annual American Society of Hematology Meeting Highlighting Company’s Drug Candidates and Technology Platform
Oct 25, 2017 07:39AM Actinium Pharma (ATNM) Reports Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-B
Oct 25, 2017 07:30AM Actinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-B
Oct 16, 2017 07:30AM Actinium Pharmaceuticals to Present at BIO Investor Forum
Oct 4, 2017 07:31AM Actinium Pharma (ATNM) Reports Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid Leukemia
Oct 4, 2017 07:30AM Actinium Pharmaceuticals Provides Update on Actimab-A Phase 2 Clinical Trial for Patients with Acute Myeloid Leukemia
Sep 20, 2017 07:30AM Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
Sep 13, 2017 07:30AM Actinium Pharmaceuticals Highlights Presence at the Society of Hematologic Oncology 2017 Annual Meeting
Sep 6, 2017 04:05PM Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference
Aug 9, 2017 07:30AM Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
Aug 2, 2017 04:05PM Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Jul 28, 2017 09:10AM Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
Jul 27, 2017 04:56PM Actinium Pharma (ATNM) Plans Offering of Common Stock and Warrants
Jul 27, 2017 04:05PM Actinium Announces Proposed Public Offering of Common Stock and Warrants to Purchase Stock
Jul 13, 2017 07:00AM Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
Jul 6, 2017 07:30AM Actinium Pharmaceuticals to Host Webinar Focused on Actimab-A and Recent Developments Related to CD33 Targeted AML Therapies on July 13, 2017 at 8:00 am ET
Jun 15, 2017 08:34AM Actinium Pharma (ATNM) Publishes Letter to Shareholders Highlighting Accomplishments & Upcoming Catalysts
Jun 15, 2017 08:30AM Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
Jun 15, 2017 07:11AM Actinium Pharma (ATNM) Appoints Nitya Ray Ph.D. as EVP, Head of Product Development, Manufacturing & Supply Chain
Jun 15, 2017 07:00AM Actinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Developme
Jun 12, 2017 07:00AM Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
Jun 9, 2017 07:31AM Actinium Pharma (ATNM) Names Sandesh Seth as CEO
Jun 9, 2017 07:30AM Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer
Jun 8, 2017 07:30AM Actinium Pharmaceuticals Highlights Presence at Upcoming Society of Nuclear Medicine and Molecular Imaging Annual Meeting
Jun 8, 2017 07:00AM UPDATE – Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
May 31, 2017 07:30AM Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
May 24, 2017 09:24AM Actinium Pharma (ATNM) Says EMA Granted Orphan Designation for Actimab-A
May 24, 2017 09:23AM Actinium Pharmaceuticals Granted Orphan Designation from the European Medicines Agency for Actimab-A
May 23, 2017 07:30AM Actinium Pharmaceuticals to Present Actimab-A Data at the 10th International Symposium on Targeted Alpha Therapy
May 17, 2017 07:00AM Actinium Pharmaceuticals Announces Appointment of Hematology Expert Dr. Richard Stone of the Dana-Farber Cancer Institute to its Scientific Advisory Board
May 10, 2017 07:17AM Actinium Pharma (ATNM) Says It's Cleared by Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
May 10, 2017 07:00AM Actinium Pharmaceuticals Receives Clearance from Health Canada to Initiate Pivotal Phase 3 SIERRA Trial of Iomab-B
Apr 18, 2017 07:00AM Actinium Pharmaceuticals Announces Sponsorship of the Acute Leukemia Forum 2017
Mar 28, 2017 07:02AM Actinium Pharma (ATNM) Appoints Ajit Shetty to the Board of Directors
Mar 28, 2017 07:00AM Actinium Pharmaceuticals Appoints Pharmaceutical Industry Executive Ajit S. Shetty, Ph.D., to the Company’s Board of Directors
Mar 21, 2017 07:01AM Actinium Pharma (ATNM) Receives Positive Scientific Advice from EMA for Iomab-B
Mar 21, 2017 07:00AM Actinium Announces Receipt of Positive Scientific Advice from the European Medicines Agency for Iomab-B
Mar 16, 2017 05:30PM Actinium Pharmaceuticals to Sponsor 4th Annual Summit on Hematologic Malignancies
Mar 7, 2017 07:00AM Actinium Pharmaceuticals to Present at 29th Annual ROTH Conference
Feb 28, 2017 07:06AM Actinium Pharma (ATNM) Announces Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and Technology Platform
Feb 28, 2017 07:00AM Actinium Announces Expansion of Intellectual Property Portfolio with Notice of Allowance for U.S. Patent Related to Actimab-A, Actimab-M and the Company’s Technology Platform
Feb 23, 2017 07:00AM Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
Feb 21, 2017 07:00AM Actinium Pharmaceuticals Announces Hiring of Steven Price to Position of Vice President, Clinical and Commercial Strategy
Feb 14, 2017 07:00AM Actinium Pharmaceuticals to Attend the BMT Tandem Meetings, the Combined Annual Meetings of Two Leading Transplant Organizations
Feb 13, 2017 04:15PM Actinium Pharmaceuticals to Present at Source Capital Group’s 2017 Disruptive Growth & Healthcare Conference
Feb 13, 2017 07:00AM Actinium Pharmaceuticals’ Company Presentation at BIO CEO & Investor Conference to Provide Highlights of Recently Announced Actimab-M Trial in Multiple Myeloma 
Feb 9, 2017 07:00AM Actinium Pharmaceuticals to Present at BIO CEO & Investor Conference
Feb 7, 2017 08:02AM Actinium Pharma (ATNM) Expands with Initiation of Phase 1 Trial of Actimab-M in Multiple Myeloma
Feb 7, 2017 08:00AM Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma
Jan 24, 2017 07:00AM Actinium’s Chief Medical Officer, Dr. Mark Berger, to Present Talk Titled, Iomab-B: Radiolabeled CD45 at the 3rd Annual Expert Forum on Acute Leukemias and Myeloproliferative Neoplasms
View More Recent Stories View Older Stories